For the research conducted on endometrial cancer, the most frequently used models have been immortalized 2D cell lines and mouse models. 2D cell culture systems lack the 3D structure that is fully represented in the primary endometrium, therefore influencing the microenvironment and orientation that allows glandular cells to function. Mouse models also can't accurately represent the human endometrium biology; thus, reliable biological models are required to emulate the human endometrial cancer biology.
The importance of 3D organoid models has become apparent in recent years, as they are able to replicate the biological behavior and the genetic complexity of tumors. Endometrial cancer organoid models can be expanded across multiple passages, helping describe the behavior of tumors and the response to various medications to broaden the understanding of the disease, leading to the creation of effective and novel tailored therapeutic strategies.
Preclinical Drug Screening & Validation
These models provide a high-throughput platform for assessing drug efficacy, synergy, and resistance mechanisms, supporting the translation of novel therapeutic candidates.
Biomarker Discovery and Validation
Organoids enable the correlation between drug response and molecular profiles, aiding in the identification of predictive biomarkers for precision oncology.
Tumor Biology & Disease Modeling
They offer a physiologically relevant system to study tumor drivers, microenvironment crosstalk, metastatic progression, and specific pathophysiology in a controlled setting.
Leveraging expertise in stem cell biology, optimized endometrial-specific matrix formulations, and rigorous quality control, Alfa Cytology delivers physiologically relevant and reproducible endometrial cancer organoid models. Based on this model, we offer customized protocol design, advanced culture expansion, and comprehensive molecular validation to ensure model accuracy and utility in downstream research.
Alfa Cytology's endometrial cancer organoid development services encompass a comprehensive range of biologically relevant models, derived not only to cover a spectrum of endometrial cancer subtypes, but also from diverse biological sources. This customized approach ensures that researchers have a versatile and representative toolkit for their research needs.
By Types
In addition to the provided model development services, we also provide research services powered by our experts and technologies, so these include organoid-based fundamental research services like coculture with immune or stromal cells and invasion assays, as well as organoid-based preclinical research services like high-throughput compound screening, combination therapy, and biomarker studies.
Alfa Cytology established and functionally validated endometrial cancer organoid models. Organoids were derived from primary tumor tissues via enzymatic digestion, embedded in a defined matrix, and then expanded in a specialized medium to support long-term culture and biobanking. Utilizing this robust platform, a co-culture assay was conducted to investigate tumor-stroma interactions. Exposure of endometrial cancer organoids to conditioned medium from cancer-associated fibroblasts (CAFs) resulted in a time-dependent, significantly enhanced proliferation rate, experimentally validating the pro-tumorigenic role of the tumor microenvironment. This model system thus demonstrates high physiological relevance for mechanistic studies and preclinical evaluation.
Fig.1 Development and validation of endometrial cancer organoid models. (A) Schematic workflow for the generation of tumor organoids. (B) Functional assessment demonstrating that conditioned medium from CAFs significantly promoted the proliferation of endometrial cancer organoids. Data are presented as mean ± SEM (n=5; ***p < 0.001).
Alfa Cytology is committed to providing scientifically rigorous, customizable organoid models and derivative research services to accelerate endometrial cancer research and therapeutic development. For project inquiries, collaboration opportunities, or detailed service specifications, please contact our scientific team to discuss how we can support your specific research needs.
Reference
For research use only.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.
